Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  decitabine
Find trials that include:  Any drugs shown
Results 1-25 of 33 for your search:
Start Over
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: T2009-003, NCI-2012-00563, NCT01483690
Dasatinib and Decitabine in Treating Patients with Accelerated or Blastic Phase Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0333, NCI-2012-00014, CA180357, NCT01498445
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 2652.00, NCI-2012-02224, 2652, NCT01729845
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Decitabine and Vemurafenib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
Vosaroxin and Decitabine in Treating Older Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2013-0099, NCI-2013-01665, NCT01893320
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Omacetaxine Mepesuccinate and Decitabine in Treating Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and over
Trial IDs: 2013-0812, NCI-2014-02157, NCT02141477
Ruxolitinib Phosphate and Decitabine in Treating Patients with Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0344, NCI-2014-02299, NCT02257138
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 1106011736, NCI-2012-01959, CDR0000712322, 8854, AECM-8854, NCT01627041
Cladribine, Cytarabine, and Decitabine in Treating Patients with Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2011-0987, NCI-2012-00145, NCT01515527
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371003, NCI-2012-01145, 2012-000684-24, NCT01546038
Decitabine, Vorinostat, and Donor Natural Killer Cells in Treating Patients with High-Risk Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: MT2012-04, NCI-2012-01320, 1204M13602, 2011LS124, NCT01593670
Genomic Predictors of Decitabine Response in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201210102, NCI-2012-01576, NCT01687400
Decitabine and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: HO11421, NCI-2012-01325, 2012-0217-CP002, 2012-0217-CP005, 2012-0217-CP012, NCT01707004
Decitabine or Azacitidine in Treating Patients with De Novo or Secondary Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0507, NCI-2012-02215, NCT01720225
Different Schedules of Decitabine in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2012-1017, NCI-2013-00463, NCT01786343
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 12-099, NCI-2013-00736, NCT01829503
Decitabine and Midostaurin in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: HEMAML0022, NCI-2013-00868, 25737, NCT01846624
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0225, NCI-2013-02252, NCT01893372
Eltrombopag Olamine and Decitabine in Treating Patients with Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0590, NCI-2014-01276, NCI-2014-00856, NCT02010645
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: I 245213, NCI-2013-02425, NCT02029417
Selinexor (KPT-330) in Older Patients With Relapsed AML
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: KCP-330-008, NCI-2014-00820, NCT02088541
Start Over